Takeda Joins With U.S. Group For Schizophrenia Drug Model
This article was originally published in PharmAsia News
Takeda Pharmaceutical is joining with a nonprofit U.S. group to create a development model of schizophrenia at the molecular level
You may also be interested in...
The European Medicines Agency has provided an update on the status of its review of Gilead’s investigational antiviral in the treatment of COVID-19.
Sandoz has published the results of two studies involving the company’s pegfilgrastim biosimilar and glatiramer acetate generic. For the former, Sandoz observed cost savings could run eventually to tens of millions of dollars per year with patient conversion and expanded access.
UK proposals for limited cooperation with the EU in medicines regulation, including the recognition of certificates and inspections, are one glimmer of light in an otherwise uncertain post-Brexit regulatory scenario for the UK. But time pressures and political spats over the future relationship could throw the whole enterprise into doubt.